Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (674)	6/7/2004 9:03:43 PM
From: Miljenko Zuanic	of 897

<<ONXX' BAY 43-9006 posted middling results as monotherapy, but these combo results in melanoma look a bit better, and may pop the stock back up for a bit:>> Tuck, do not get me wrong! I am not against 9006, not yet! , Only that ONXX stock price was ahead of itself. Yes, metastatic melanoma data are intriguing and indicate drug activity. BUT 40% RR IS WAY TOO HIGH for my taste, and from what to expect from this combination. So, the next question is Pts selection and how they got this results? This leave me with taste that RCC was also done with special Pts selection, at least as speculation. I do not trust them and will need ALL data to make sound opinion. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next